Publications
154
Citations
2,674
Est. group size
~6
Recurring co-author estimate
Active years
31
Publishing since 1996
This researcher focuses on health economics and policy analysis of adult vaccination programs, especially pneumococcal and influenza vaccines, in the United States. Much of the work evaluates the cost-effectiveness, budget impact, and public health value of different vaccine formulations and strategies, including their effects on racial and socioeconomic disparities in vaccine-preventable disease. The research combines epidemiological data with economic modeling to inform vaccine policy decisions for older and underserved adult populations.
Publication output has been fairly steady with some fluctuation over the past decade, showing a notable peak in 2024 followed by continued activity into 2025-2026.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Impact of Serotype Uncertainty on Adult Pneumococcal Vaccine Options: A Value of Information Analysis
American Journal of Preventive Medicine · 2026
- Public health effects of adult pneumococcal vaccination choice amid increased serotype 4 rates in US subpopulations
Public Health · 2025
- Cost-effectiveness and budget impact analyses of the 24-valent pneumococcal conjugate vaccine in adults aged 50 and older
Vaccine · 2025
- A budget impact analysis of 15- or 20- valent pneumococcal conjugate vaccine use in all US adults aged 50–64 years old compared to those with high-risk conditions from US payer perspective
BMC Public Health · 2025
- Burden of employment loss and absenteeism in adults and caregivers of children with sickle cell disease
Blood Advances · 2024
- Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50 years or older
Vaccine · 2024
- Pneumococcal Vaccination Strategies in 50-Year-Olds to Decrease Racial Disparities: A US Societal Perspective Cost-Effectiveness Analysis
Value in Health · 2024
- Cost-Effectiveness and Public Health Impact of 24-Valent Pneumococcal Conjugate Vaccine Compared With the Recommended Pneumococcal Vaccines in Older Adults
American Journal of Preventive Medicine · 2024
- Changes in the cost‐effectiveness of pneumococcal vaccination and of programs to increase its uptake in U.S. older adults
Journal of the American Geriatrics Society · 2024
- Smoking and serological response to influenza vaccine
Human Vaccines & Immunotherapeutics · 2024
- Corrigendum to “Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50 years or older” [Vaccine 42 (2024) 3024–3032]
Vaccine · 2024
- Sex and Psychosocial Differences in Acute Stress Symptoms Prior to Open-Heart Surgery
International Journal of Behavioral Medicine · 2024
- EE494 A Budget Impact Analysis of Newer Pneumococcal Conjugate Vaccine Use in All US Adults Aged 50-64 Years Old Compared to Current Recommendations from US Payer Perspective
Value in Health · 2024
- Cost-effectiveness of an in-development adult-formulated pneumococcal vaccine in older US adults
Vaccine · 2023
- Societal Cost of Racial Pneumococcal Disease Disparities in US Adults Aged 50 Years or Older
Applied Health Economics and Health Policy · 2023
- Vaccine×13
- Human Vaccines & Immunotherapeutics×8
- Journal of the National Medical Association×5
- Blood Advances×4
- Journal of the American Geriatrics Society×4
- Susan Reed
Medicine · Indiana University
- Veerupaxagouda Patil
Medicine · The Ohio State University
- Fenghua Zhang
Medicine · Purdue University West Lafayette
- Jennifer Schrock
Medicine · The Ohio State University
- Yohannes A. Mebratu
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile